Foresight Diagnostics Announces Three Presentations Highlighting Clinical Studies Using Patented PhasED-Seq® MRD Platform at the 64th American Society of Hematology Annual Meeting and Exposition

PhasED-Seq ctDNA detection enables accurate and predictive treatment response monitoring and clinical prognosis in patients with B-cell lymphoma.A...

Related Keywords

United States ,American ,Jake Chabon ,Davidm Kurtz ,Mark Roschewski ,Linkedin ,National Cancer Institute ,American Society Of Hematology Annual Meeting ,Stanford University School Of Medicine ,Ernestn Morial Convention Center ,Program Committee ,Cancer Research ,Lymphoid Malignancies Branch ,Co Ting Keh ,Division Of Oncology ,American Society ,Hematology Annual Meeting ,Convention Center ,New Orleans ,Tessa Therapeutics ,Hodgkin Lymphoma ,Potential Surrogate Endpoint ,Pooled Analysis ,Clinical Trial ,Foresight Diagnostic ,Ultrasensitive Circulating Tumor ,Classical Hodgkin Lymphoma ,Stanford University School ,Predicts Outcomes ,Frontline Therapy ,Nat Biotechnol ,About Foresight ,